Your Horse Was Put on Lasix—Here’s What You Should Know

Last updated: September 20, 2026

By: Miles HenryFact Checked

If your vet or trainer has recommended Lasix for your horse, you probably want to know what it does, whether it can help, and what the tradeoffs are. Lasix has been used for decades in horses that work hard – including racehorses, barrel horses, polo ponies, and some event horses – to help manage exercise-induced pulmonary hemorrhage (EIPH), bleeding in the lungs during strenuous exercise.

I’ve used Lasix for our racehorses and a barrel horse. Below, I explain what it does, why it is used in different performance horses, its risks and limitations, alternatives for managing EIPH, and the competition rules owners need to check before entering—including current HISA rules for Thoroughbred racing.

What Is Lasix for Horses?

Lasix is the brand name for furosemide, a loop diuretic originally developed for human patients with congestive heart failure and kidney disease. In horses, it blocks sodium, potassium, and chloride reabsorption in the kidneys, sharply increasing urine output and reducing total blood volume within hours of administration.

During intense exercise, pressure in the lung circulation rises dramatically. In horses susceptible to EIPH, that pressure is associated with pulmonary capillary stress failure and bleeding into the airways. Furosemide increases urine production and reduces plasma volume, which can lower pulmonary vascular pressures associated with EIPH. For the physiology of EIPH itself, including how it’s graded and what else can cause a nosebleed, see our EIPH guide.

Lasix is most closely associated with Thoroughbred and Standardbred racing, but EIPH isn’t limited to racetrack horses. It can occur in horses working at high intensity, including barrel horses, polo ponies, eventers, cutters, and steeplechasers. The likelihood of bleeding, the value of treatment, and the rules for medication can differ by discipline, horse, and governing organization, so the decision should start with a veterinary diagnosis and the rules of the competition where you plan to enter.

Why a Vet Might Recommend Lasix

A vet may bring up Lasix when a horse shows signs that raise concern for EIPH, such as poor recovery after hard work, an unexplained drop in performance, coughing, or visible blood at the nostrils after a run. Post-exercise endoscopy is commonly used to look for evidence of airway bleeding and to grade its severity, but your veterinarian may also consider other respiratory and performance issues before recommending treatment.

The secondary effect of the drug—fluid loss—is the contested part. A horse on Lasix loses meaningful fluid weight before competition. Because that can affect the weight a horse carries at speed, it is both a treatment side effect and the source of the performance-enhancement argument that follows the medication into every discipline that allows it.

EIPH in Racehorses, Barrel Horses, Polo Ponies, and Event Horses

EIPH has been documented well beyond the racetrack. Published research has found it in barrel racing horses, and it’s also been reported in polo ponies, eventers, and other horses working at high intensity for short bursts. The American College of Veterinary Internal Medicine’s consensus statement describes EIPH as occurring in horses subjected to strenuous exercise generally, not just Thoroughbreds and Standardbreds.

What’s different by discipline is how much evidence exists and what it actually shows. The Thoroughbred and Standardbred research base is large, and it consistently shows furosemide reduces EIPH incidence and severity. The barrel-racing research is much thinner. A 2018 study out of the Pacific Northwest and a separate 2016 study out of Alberta both documented EIPH in barrel horses, but neither was a controlled crossover trial comparing the same horses with and without furosemide, so they can’t establish how much the drug helps in that discipline specifically. Some of the available literature has even found no clear effect of EIPH itself on barrel-racing performance, which is a genuinely different picture than what shows up in flat racing.

Lasix is sometimes used in barrel horses and other high-performance horses to manage suspected or diagnosed EIPH, but discipline-specific evidence and competition rules vary – don’t assume the racing research applies one-to-one to your event.

Benefits, Risks, and Recovery

The core disagreement isn’t whether furosemide works for EIPH – the ACVIM consensus statement found moderate- to high-quality evidence that furosemide reduces the incidence and severity of EIPH in racehorses. It also found an association between furosemide administration and superior race performance, which helps explain why the medication remains controversial even when it’s used to treat a genuine condition. The panel made a strong recommendation that EIPH be considered a disease, but only a weak recommendation for using furosemide to manage it – a more cautious conclusion than the drug’s defenders sometimes suggest.

Supporters argue that untreated bleeding is a real welfare issue and that banning treatment doesn’t stop the underlying condition, only the intervention. Critics argue that any competition-day medication with a performance association deserves scrutiny, regardless of the medical justification. Both sides can be right about different things at once. Furosemide can be genuinely effective medicine for a horse that needs it, and its use can still influence competition-day variables such as hydration status and weight, which is why regulators continue to debate its place in competition.

Furosemide is widely used under veterinary supervision, but it isn’t risk-free. Its diuretic effect can contribute to fluid and electrolyte changes, and horses need adequate time and access to water and forage to rehydrate afterward. Discuss a hydration and recovery plan with your vet as part of any Lasix protocol, not as an afterthought.

Lasix in Horse Racing: Current HISA Rules

This section covers HISA-covered Thoroughbred racing specifically. If you compete in another discipline, see the next section instead.

In racing conversation, people often call this “race-day Lasix,” though HISA’s rule is written as a restriction on furosemide administered within the 48 hours before a race. American furosemide regulation has gradually changed since 2020, with HISA narrowing where the drug is permitted, leading to a scheduled 2026 review required by statute.

• Pre-HISA (before 2023): Furosemide was permitted in virtually all races across North America, with state racing commissions regulating individually and no federal uniformity.
• 2021: The Kentucky Derby and Breeders’ Cup adopted Lasix-free conditions, showing that elite races could be conducted under those restrictions. That experience didn’t settle the wider argument, though, because stakes horses are generally managed with different resources, schedules, and replacement economics than the overnight claiming population.
• May 2023: HISA’s Anti-Doping and Medication Control Program launched. Race-day furosemide was immediately banned in all 2-year-old races and all stakes races. All other categories received a three-year exemption pending scientific review.
• 2024-2025: HISA funded three studies (roughly $773,500 total across Washington State University, the University of Florida, and Nationwide Children’s Hospital), with final reports required by January 2026 ahead of the board’s statutory review.
• April-May 2026: HISA’s Board of Directors voted unanimously on April 24 to preserve the existing two-tier system rather than extend the ban to all races. HISA announced the decision May 5, and the modification took effect May 23, 2026.

For owners and trainers, the practical takeaway is simple: the rules didn’t change. Lasix remains prohibited in stakes and 2-year-old races but continues to be permitted in other race categories under HISA guidelines. That outcome required the board to unanimously make four findings, including that furosemide has no performance-enhancing effect on individual horses – a statutory finding the board made after considering its Furosemide Advisory Committee’s report, not a claim that settles the broader scientific debate discussed above.

The policy debate often centers on Derby horses and elite racing, but most owners operate far from that level. For a small stable, medication rules are also management decisions involving veterinary costs, race frequency, and whether a horse remains economically viable. The view from a Fair Grounds claiming barn is different in ways that matter to the sport’s operating economics. In many claiming barns, a horse may need to run roughly every 25 to 35 days to help cover its keep. That timetable varies with purse levels, claiming price, training costs, soundness, and the individual horse, but it’s a real part of the owner’s calculation. Managed on furosemide, a confirmed bleeder can maintain a normal race schedule and compete at its natural class level; without it, the same horse needs longer recovery between starts and faces a higher risk of visible bleeding episodes that affect its value. For the full picture of what racehorse ownership costs, see our racehorse ownership cost guide.

In a March 2026 NYTHA survey reported by BloodHorse, 81% of respondents said they’d race less often if furosemide were banned in every race, while 80% said they’d already bypassed stakes opportunities to preserve Lasix eligibility in overnight races. Those findings describe horsemen’s reported decisions and expectations; they don’t independently prove what the industry-wide result of a full ban would be. For bleeders in the two-year-old ranks, where HISA’s ban had already been in effect for two years at the time of the survey, 47% of NYTHA members reported increased EIPH incidence and greater severity, and only 27% saw minimal or no change.

Two of the three HISA-funded studies matter most for owners. The Nationwide Children’s Hospital study tracked repeated furosemide dosing effects on electrolyte homeostasis and urinary excretion in exercising Thoroughbreds – safety-of-use data directly relevant to horses racing every three to four weeks, the claiming barn model. Washington State University researchers, led by Dr. Warwick Bayly and Dr. Macarena Sanz, were funded to analyze data from roughly 30,000 racehorses. Their project was designed to examine whether regular furosemide treatment was associated with more starts and longer careers, while also comparing two-year-old racing before and after the juvenile restriction. The study question matters to the welfare argument either way. Its final findings should be read in the context of the study’s methods, population, and limitations rather than treated as a stand-alone answer to the entire Lasix debate.

Lasix Rules for Barrel Racing, Eventing, Polo, and Other Competition

Barrel racing, rodeo, and many local or regional associations set their own medication rules, and those rules can vary significantly by organization and even by individual event. Some organizations require disclosure, documentation, or specific withdrawal periods; others may restrict or prohibit furosemide. Eventing and polo, when governed by national or international federations, follow their own medication and doping frameworks, separate from HISA and often more restrictive than U.S. Thoroughbred racing.

The bottom line for any non-racing competitor: don’t assume a rule you’ve read about HISA or Thoroughbred racing applies to your discipline. Contact your sanctioning body directly, read the current medication rule for the specific event and class you’re entering, and build in enough lead time to confirm your horse’s treatment plan complies before you haul to the competition.

Alternatives and EIPH Management

None of the available alternatives replicate furosemide’s primary mechanism – acutely reducing blood volume and pulmonary capillary pressure before exertion. They address adjacent factors. Some management approaches may help reduce EIPH severity in individual horses, but their effect isn’t as consistent or as well established as furosemide’s effect, and a veterinarian should guide the plan. In a competition schedule that depends on regular starts, management changes such as longer recovery intervals or reduced frequency may be harder to put into practice.

• Equine nasal strips are among the most studied non-drug options. They’re designed to support the nasal passages and reduce inspiratory airway resistance during hard exercise. Some studies have found reduced EIPH severity, but results vary, and furosemide generally has a larger effect in controlled research. Nasal strips may be worth discussing with your veterinarian as one part of an individual horse’s management plan, not as an assumed replacement for Lasix.
• Selective breeding is often raised as a long-term strategy because EIPH appears to have heritable components. It isn’t a practical answer for the horse already in work this season, though, and breeding-policy outcomes take generations to evaluate.
• Training modification may include graduated conditioning, more recovery between hard efforts, or a less demanding competition schedule. These changes can be practical management tools for some horses, but the right plan depends on the horse’s diagnosis, workload, recovery, and veterinary guidance.
• Nutrition and recovery still matter – forage quality, hydration, and a horse’s overall respiratory health all play a role. No dietary program has been shown to duplicate furosemide’s acute effect on EIPH, so discuss any EIPH-management plan with your equine veterinarian.

Lasix as a Handicapping Signal

This section is specific to horse racing bettors. A change in a horse’s Lasix status is worth noticing, but it isn’t a stand-alone betting angle. First-time Lasix may reflect a veterinarian’s recommendation, a change in race conditions, a horse returning from stakes company, or a barn’s broader management decision. The program doesn’t tell you why the change was made or whether the horse has confirmed EIPH, so use it alongside form, class, trainer patterns, workout history, and race conditions – not as proof a horse will improve. For the complete handicapping framework these signals fit into, see our 4-point filter guide.

FAQ

Sources

• HISA: Board Votes, Status Quo Remains for Lasix (May 5, 2026)
• ACVIM Consensus Statement on EIPH (Hinchcliff et al., JVIM 2015)
• Tracheobronchoscopic Assessment of EIPH in Barrel Racing Horses (Leguillette et al., JVIM 2016)
• EIPH in Barrel Racing Horses in the Pacific Northwest (Gold et al., JVIM 2018)
• WSU: Study on Furosemide and Career Longevity
• BloodHorse: NYTHA Survey on a Full Lasix Ban